BioSpace News Archive

Photodynamic therapy finds application in the treatment of various health conditions including basal cell carcinomas, actinic keratosis, and other skin diseases.

Pompe disease is a genetic mutation that generally occurs in infants. In this condition, the body is unable to produce a specific enzyme that is responsible for breaking glycogen into a simple sugar.

U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K. immediately

[02-December-2020] SAN DIEGO , Dec. 2, 2020 /PRNewswire/ -- Agena Bioscience, a global provider of low-cost and high-throughput molecular testing solutions, today announced the launch of the MassARRAY ® SARS-CoV-2/Flu Panel (RUO) for qualitative detection of SARS-CoV-2, influenza A, and influenza B viral RNA. The panel is available for research use only.

Rapid and substantialimprovement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment

Tetra Bio-Pharma Inc. ( TSX:TBP ) ( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, today announced it has completed Investigational New Drug (IND) -enabling toxicology, clearing the way for human clinical trials for its novel drug candidate ARDS-003.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed an agreement to settle its ongoing patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc. As a result of this agreement, both parties will drop their respective claims relating to the p

Calithera Biosciences, Inc announced that the compensation committee of the company’s board of directors granted three new employees a non-qualified stock option to purchase an aggregate of 53,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on November 30, 2020.

New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro poietin level Multiple analyses evaluate cardiovascular safety and efficacy of roxadustat in patients with anemia of chronic kidney disease (CKD ) regardless of dialysis status

BD, a leading global medical technology company, announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems across its six global manufacturing locations and add a new manufacturing facility in Europe.